1. Bauer S. et al.: Systemic resistin is increased in type 2 diabetic patients treated with loop diuretics. J. Diabetes Complications, 2011, 25:377-381.<a href="https://doi.org/10.1016/j.jdiacomp.2011.06.001" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.jdiacomp.2011.06.001</a>
3. Ebtesam A Al-Suhaimi, Adeeb Shehzad.: Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. European Journal of Medical Research, 2013, 18:12.<a href="https://doi.org/10.1186/2047-783X-18-12" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/2047-783X-18-12</a>
4. Fujinami A. et al.: Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clinica Chimica Acta, 2004; 339 (1-2): 57-63.<a href="https://doi.org/10.1016/j.cccn.2003.09.009" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.cccn.2003.09.009</a>
6. Janke J. et al.: Resistin gene expression in human adipocytes is not related to insulin resistance. Obes. Res., 2002; 10: 1-5.<a href="https://doi.org/10.1038/oby.2002.1" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/oby.2002.1</a>
7. Jinhua Yin et al.: Measurement of Salivary Resistin Level in Patients with Type 2 Diabetes. International Journal of Endocrinology, 2012; 2012: Article ID 359724, 5 p.<a href="https://doi.org/10.1155/2012/359724" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1155/2012/359724</a>
8. Lauders M et al.: Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Horm Metab Res., 2010 Apr;42(4):268-7310.1055/s-0029-1243638
9. Lee J.H. et al.: Circulating resistin levels are not associated with obesity or insulin resistance in humans, and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J. Clin. Endocrinol. Metab., 2003; 88: 4848-4856.<a href="https://doi.org/10.1210/jc.2003-030519" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1210/jc.2003-030519</a>
11. Meier U., Gressner A.M.: Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clin Chem., 2004; 50: 1511-1525.
12. Nagaev I, Smith U.: Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem. Biophys. Res. Commun., 2001; 285: 561-564.
13. Rajala M. et al.: Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes, 2004; 53 (7): 1671-1679.<a href="https://doi.org/10.2337/diabetes.53.7.167115220189" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.2337/diabetes.53.7.167115220189</a>
17. Tokuyama Y. et al.: Serum resistin level is associated with insulin sensitivity in Japanese patients with type 2 diabetes mellitus. Metabolism, 2007; 56 (5): 693-698.<a href="https://doi.org/10.1016/j.metabol.2006.12.01917445546" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.metabol.2006.12.01917445546</a>
18. Vozarova De Courten B. et al.: High serum resistin is associated with an increase in adiposity but not worsening of insulin resistance in Pima Indian. Diabetes, 2004; 53 (9): 1279-1284.<a href="https://doi.org/10.2337/diabetes.53.5.127915111497" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.2337/diabetes.53.5.127915111497</a>